Pulmonary arterial hypertension trials in South Korea

In South Korea 13 Also abroad 305

13 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
An Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
Where
Seoul
Age
18 years and over
People
344 worldwide
Run by
Insmed Incorporated
See details and how to joinNCT07234032 · EU 2025-521769-29-00
Phase 3Taking people
A Study Providing Treatment Access in Participants With Pulmonary Hypertension Completing a Parent Study and Having no Other Option
Where
Daejeon, Incheon, Seoul
Age
2 years and over
People
280 worldwide
Run by
Actelion
See details and how to joinNCT05179876 · EU 2023-506791-27-00
No phaseNot yet taking people in South Korea
A Study of Opsynvi in Adults Participants With Pulmonary Arterial Hypertension in Korea
Where
Busan
Age
18 years and over
People
333
Run by
Janssen Korea, Ltd., Korea
See details and how to joinNCT07890285
Phase 2Taking people
Study of TX000045 in Participants With Pulmonary Hypertension Due to Interstitial Lung Disease
Where
Gyeonggi-do, Seoul
Age
18 years to 80 years
People
25 worldwide
Run by
Tectonic Operating Company, Inc.
See details and how to joinNCT07473700
Phase 3Taking people
Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
Where
Incheon, Seoul, Wŏnju
Age
18 years and over
People
344 worldwide
Run by
Insmed Incorporated
See details and how to joinNCT07179380 · EU 2025-521558-40-00
Phase 2Taking people
Study of REGN13335 in Adult Participants With Pulmonary Arterial Hypertension (PAH)
Where
Namdong-gu, Seoul
Age
18 years and over
People
99 worldwide
Run by
Regeneron Pharmaceuticals
See details and how to joinNCT07318597 · EU 2024-514754-79-00
Phase 3Taking people
Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)
Where
Seoul
Age
18 years to 75 years
People
330 worldwide
Run by
Gossamer Bio USA, Inc.
See details and how to joinNCT06274801 · EU 2023-506334-75-00
Phase 3Taking people
A Study to Evaluate the Efficacy and Safety of Once Daily Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Arterial Hypertension (PAH)
Where
Busan, Incheon, Seoul
Age
18 years to 75 years
People
344 worldwide
Run by
Insmed Incorporated
See details and how to joinNCT07481981 · EU 2026-525265-48-00
Phase 3Enrolling by invitation
A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension
Where
Incheon, Seoul
Age
18 years and over
People
1,000 worldwide
Run by
United Therapeutics
See details and how to joinNCT03683186 · EU 2023-509305-68-00
Phase 3Taking people
An Adaptive Program of IKT-001 in Pulmonary Arterial Hypertension (PAH)
Where
Gwangju, Seoul
Age
18 years to 75 years
People
486 worldwide
Run by
Inhibikase Therapeutics
See details and how to joinNCT07365332 · EU 2024-520218-23-00
Phase 4Taking people
Clinical Trial to Evaluate the Efficacy and Safety in Concomitant Administration of Macitentan and Dapagliflozin in Patients With Heart Failure With Mildly Reduced and Preserved Ejection Fraction (HFmrEF and HFpEF) and Combined Pre- and Post-capillary Pulmonary Hypertension (CpcPH)
Where
Busan, Chungju, Daegu, Daejeon, Gwangju, Incheon, Seoul, Wŏnju, Yangsan
Age
19 years and over
People
64
Run by
Gachon University Gil Medical Center
See details and how to joinNCT07147114
Phase 1Not yet taking people in South Korea
PNEUMOSTEM® for Improving Respiratory Outcomes in Very Premature Infants Diagnosed With Early Pulmonary Arterial Hypertension
Where
Seoul
Age
1 day to 14 days
People
12
Run by
Samsung Medical Center
See details and how to joinNCT07368088
Phase 4Not yet taking people in South Korea
Efficacy of Inhaled Nitric Oxide in Congenital Diaphragmatic Hernia
Where
Gwangju, Seoul
Age
1 Minute to 14 days
People
40
Run by
Asan Medical Center
See details and how to joinNCT07247240